8-KOther Events

ABBOTT LABORATORIES 8-K Report (Jul 1, 2004)

Filed July 1, 2004For Securities:ABT

Summary

This 8-K filing by Abbott Laboratories (ABT) from July 1, 2004, primarily details the financial impact of the Hospira spin-off, which was completed on April 30, 2004. As a result, Hospira's historical financial results are now presented as Discontinued Operations. The filing provides adjusted financial statements for 2003 and the first quarter of 2004, reflecting the removal of Hospira's operations from Abbott's continuing operations. Furthermore, Abbott has also adjusted its business segment reporting, effective January 1, 2004, to align with the post-spin-off structure. The company also reiterates its use of non-GAAP financial measures, such as 'Earnings from Continuing Operations Excluding One-time Charges,' to provide investors with a clearer view of ongoing business performance by excluding unusual or unpredictable factors.

Key Highlights

  • 1The Hospira spin-off was completed on April 30, 2004, and its historical results are now reported as Discontinued Operations.
  • 2Abbott has provided adjusted financial statements for Q1 2003, Q2 2003, Q3 2003, Q4 2003, Full Year 2003, and Q1 2004, excluding Hospira's financial impact.
  • 3Business segment reporting has been updated to reflect reclassifications effective January 1, 2004, in line with the post-Hospira spin-off structure.
  • 4The filing details the reclassification of specific product sales (e.g., U.S. Pharmaceutical Sales, U.S. Hospital Products Sales, International Hospital Products Sales) due to the spin-off.
  • 5Abbott utilizes non-GAAP financial measures like 'Earnings from Continuing Operations Excluding One-time Charges' to offer investors a better understanding of ongoing operational performance.
  • 6Significant one-time charges impacting reported earnings in 2003 included in-process R&D for acquisitions, the Ross settlement, and transition/separation charges from the Hospira spin-off.

Frequently Asked Questions

The primary purpose of this filing is to report the financial impact of the completed spin-off of Hospira, Abbott's former hospital products business. It provides updated financial statements that separate Hospira's historical results as 'Discontinued Operations' and presents Abbott's 'Continuing Operations'.

Following the spin-off, Hospira's financial results up to the separation date are no longer part of Abbott's continuing operations. They are now presented separately as 'Discontinued Operations,' allowing investors to better assess the performance of Abbott's ongoing businesses.

Abbott uses non-GAAP measures like 'Earnings from Continuing Operations Excluding One-time Charges' to provide a clearer picture of its ongoing business performance. These measures adjust for items that are unusual or unpredictable, such as certain acquisition-related costs or legal settlements, which management believes helps investors better evaluate the core operational results.

Yes, the filing details several significant after-tax charges in 2003 that were excluded from the non-GAAP 'Earnings from Continuing Operations Excluding One-time Charges.' These include charges related to in-process R&D for acquisitions, the settlement of the Ross enteral nutrition investigation, and transition/separation costs associated with the Hospira spin-off.